• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.

作者信息

Julsgaard Mette, Kjeldsen Jens, Bibby Bo M, Brock Birgitte, Baumgart Daniel C

机构信息

Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark and Horsens Hospital, Department of Medicine, Horsens, Denmark.

Odense University Hospital, Department of Gastroenterology, University of Odense, Odense, Denmark.

出版信息

Gastroenterology. 2018 Feb;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067. Epub 2017 Oct 5.

DOI:10.1053/j.gastro.2017.08.067
PMID:28988916
Abstract
摘要

相似文献

1
Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.患有炎症性肠病的哺乳期母亲母乳中的维多珠单抗浓度。
Gastroenterology. 2018 Feb;154(3):752-754.e1. doi: 10.1053/j.gastro.2017.08.067. Epub 2017 Oct 5.
2
Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.哺乳期炎症性肠病母亲的维多珠单抗在母乳中的水平。
J Crohns Colitis. 2018 Jan 5;12(1):120-123. doi: 10.1093/ecco-jcc/jjx120.
3
Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.达巴万星、磷酸特地唑胺、二磷酸奥利万星和维多珠单抗。
J Am Pharm Assoc (2003). 2014 Nov-Dec;54(6):658-62. doi: 10.1331/JAPhA.2014.14543.
4
Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease.哺乳期母亲炎症性肠病前瞻性上市后仅母乳哺乳研究中麦考酚酸浓度：结果。
Clin Pharmacokinet. 2021 Jun;60(6):811-818. doi: 10.1007/s40262-021-00985-4. Epub 2021 Feb 5.
5
Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.维多珠单抗在老年炎症性肠病患者中安全有效。
Inflamm Bowel Dis. 2017 Apr;23(4):E17. doi: 10.1097/MIB.0000000000001071.
6
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.系统评价：维多珠单抗治疗炎症性肠病的安全性
Aliment Pharmacol Ther. 2017 Jul;46(1):3-15. doi: 10.1111/apt.14075. Epub 2017 Apr 27.
7
Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.维多珠单抗在肝移植术后中重度炎症性肠病中安全有效。
Liver Transpl. 2017 Jul;23(7):968-971. doi: 10.1002/lt.24757.
8
Vedolizumab Does Not Impair Sperm DNA Integrity in Men With Inflammatory Bowel Disease.维多珠单抗不会损害炎症性肠病男性患者的精子DNA完整性。
Gastroenterology. 2019 Jun;156(8):2342-2344. doi: 10.1053/j.gastro.2019.02.041. Epub 2019 Mar 5.
9
Safety of vedolizumab in liver transplant recipients: A systematic review.维得利珠单抗在肝移植受者中的安全性：系统评价。
United European Gastroenterol J. 2019 Aug;7(7):875-880. doi: 10.1177/2050640619858050. Epub 2019 Jun 20.
10
Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.接受维多珠单抗治疗的炎性肠病患儿腹部手术后的结局
J Pediatr Surg. 2018 Sep;53(9):1706-1709. doi: 10.1016/j.jpedsurg.2017.09.019. Epub 2017 Oct 9.

引用本文的文献

1
Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review.导航炎症性肠病患者的生殖护理：全面综述。
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii16-ii30. doi: 10.1093/ecco-jcc/jjae048.
2
Common Mistakes in Managing Patients with Inflammatory Bowel Disease.炎症性肠病患者管理中的常见误区
J Clin Med. 2024 Aug 14;13(16):4795. doi: 10.3390/jcm13164795.
3
Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease.
哺乳期母亲炎症性肠病前瞻性上市后仅母乳哺乳研究中麦考酚酸浓度：结果。
Clin Pharmacokinet. 2021 Jun;60(6):811-818. doi: 10.1007/s40262-021-00985-4. Epub 2021 Feb 5.
4
Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.维多珠单抗治疗炎症性肠病孕妇的安全性：一项针对性文献综述
Therap Adv Gastroenterol. 2020 Oct 16;13:1756284820952592. doi: 10.1177/1756284820952592. eCollection 2020.
5
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.新型生物制剂（vedolizumab 和 ustekinumab）和小分子药物（托法替尼）在妊娠期的安全性：综述。
Drugs. 2020 Jul;80(11):1085-1100. doi: 10.1007/s40265-020-01346-4.
6
Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases.单克隆抗体在神经和非神经疾病向母乳中的转移。
Neurol Neuroimmunol Neuroinflamm. 2020 May 27;7(4). doi: 10.1212/NXI.0000000000000769. Print 2020 Jul.
7
2019 Expert opinion on biological treatment use in inflammatory bowel disease management.2019年关于生物治疗在炎症性肠病管理中应用的专家意见。
Turk J Gastroenterol. 2019 Nov;30(Suppl 4):S913-S946. doi: 10.5152/tjg.2019.061119.
8
Insights into the treatment of inflammatory bowel disease in pregnancy.妊娠期炎症性肠病的治疗见解。
Therap Adv Gastroenterol. 2019 May 27;12:1756284819852231. doi: 10.1177/1756284819852231. eCollection 2019.
9
A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.管理妊娠、哺乳期炎症性肠病的药理学方法：生物制剂和口服小分子治疗药物。
Drugs. 2019 Jul;79(10):1053-1063. doi: 10.1007/s40265-019-01141-w.
10
Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.孕期及哺乳期的免疫抑制剂和生物制剂：奥地利胃肠病学、肝病学、风湿病学与康复学会发布的共识报告
Wien Klin Wochenschr. 2019 Jan;131(1-2):29-44. doi: 10.1007/s00508-019-1448-y. Epub 2019 Jan 14.